RxDoctor Payments Data

Brandi Greeson

Family · Decatur, ALNPI 1982169470

Payments from drug & device makers

$5,150in general payments, 2019–2025

Across 222 payments — averaging $23.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$1K
  • Novo Nordisk$613
  • Jazz Pharmaceuticals Inc.$505
  • Harmony Biosciences LLC$318
  • Takeda Pharmaceuticals U.S.A., Inc.$282
  • AstraZeneca$242
  • plus $2K from 23 others

What the payments were for

  • Travel & lodging$94918%
  • Food & beverage$4,01178%
  • Education$1904%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,150 in reported general payments places this provider in the 90th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$22,486
Medicare patients
178
Services billed
266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate34$37,765
JardianceEmpagliflozin45$36,764
FarxigaDapagliflozin Propanediol12$14,315
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$13,596
OzempicSemaglutide14$13,343
EliquisApixaban18$11,405
VascepaIcosapent Ethyl14$9,460
LinzessLinaclotide17$8,774
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,630
Atorvastatin Calcium239$2,774
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,755
Losartan Potassium109$1,480
Amlodipine Besylate195$1,216
Fluticasone Propionate105$1,213
Albuterol Sulfate HfaAlbuterol Sulfate40$1,185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$15$37,76534 claims
Boehringer IngelheimJardiance$87$36,76445 claims
AstraZenecaFarxiga, Breztri Aerosphere$242$20,94623 claims
GSKTrelegy Ellipta$81$13,59622 claims
Novo NordiskOzempic$613$13,34314 claims
PfizerEliquis$13$11,40518 claims
AbbVieLinzess$35$8,77417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,415 family providers in Alabama.

Other family in Decatur

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →